Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Saskia M. Brachmann, Claudio Bomio-Confaglia et al.|Cancer Discovery|2022Cited by 134
OA12.03 Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLCS. Li, Benjamin G. Neel, Kwan Ho Tang et al.|Journal of Thoracic Oncology|2021Cited by 0